NCT03446703 is a NA clinical trial of SCIT in Schizophrenia, sponsored by University of Alcala.

Who is sponsoring NCT03446703?

NCT03446703 is sponsored by University of Alcala.

What drugs are being tested in NCT03446703?

Interventions in NCT03446703: SCIT, TAR.

What condition does NCT03446703 study?

NCT03446703 studies Schizophrenia.

Is NCT03446703 still recruiting?

NCT03446703 is currently completed. Last updated 27 February 2018.

Last reviewed 2018-02-27 · How we verify

NCT03446703

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SCIT Versus TAR for Outpatients With Schizophrenia

Completed NA Last updated 27 February 2018

What this trial tests

NA trial testing SCIT in Schizophrenia in 100 participants. Completed in 30 June 2017.

Timeline

1 September 2013

Primary endpoint
1 October 2016

30 June 2017

Quick facts

Lead sponsor	University of Alcala
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	1 September 2013
Primary completion	1 October 2016
Estimated completion	30 June 2017

Drugs / interventions tested

SCIT — full drug profile →
TAR

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

University of Alcala

Who can join

Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present work consists of a randomized clinical trial comparing the effectiveness of two interventions based on social cognition training in outpatients with schizophrenia. The investigators sought to compare the effect of a "targeted" (TAR) and a "broad-based" (SCIT) intervention on schizophrenia patients' performance in facial affect recognition, theory of mind and attributional style. Secondarily, the investigators compare the effect on symptomatology, general cognition and functioning. The main hypothesis was that the patient group receiving TAR would exhibit a greater improvement in emotion recognition performance at the post-intervention assessment in comparison to patients receiving the SCIT, and, conversely, patients receiving SCIT would show more effect in ToM and attributional style. To assess the durability of these effects, performance in measures of social cognition, basic cognitive functioning, symptomatology and functional capacity were assessed before (T0), after treatment (T1) and 3 months later (T2).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of SCIT

Trials testing the same drug.

NCT05510024 — Radiofrequency Ablation of Bilateral Inferior Turbinate Followed by Subcutaneous Immunotherapy Trial · NA · not yet recruiting

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other University of Alcala trials

Trials by the same sponsor.

NCT06599164 — Evaluation of Vastus Medialis Muscle Inhibition in Indoor Soccer Players With and Without ACL Injury · not yet recruiting
NCT06587412 — Treatment of Lateral Epicondylalgia With Shock Waves · NA · recruiting
NCT07333443 — Caffeine and Sport Climbing Performance · NA · completed
NCT07015008 — Sleep and Maximal Fat Oxidation · NA · completed
NCT06723821 — Noninvasive Neuromodulation in the Management of Post-COVID Musculoskeletal Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03446703 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alcala
Last refreshed: 27 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03446703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing